Alzheimer’s disease was the leading cause of death. There is no cure and no effective treatment for Alzheimer’s disease. The challenges will increase in intensity as demographic changes, particularly the aging of baby boomers, take hold. High prediction of Alzheimer’s, developed in therapy, and appropriate care modalities that likely observe significant investment. The Alzheimer’s disease Neuro Imaging Initiative (ADNI) is an ongoing, longitudinal study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). The required accomplishments of ADNI have been as follows: the development of standardized methods for clinical tests, magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebrospinal fluid (CSF).In the recent system, a large number of people are suffering from brain related diseases. Studying and finding the solutions for those diseases is the requirement of our need. Dementia is one such disease of the brain. This is most reason for the loss of cognitive functions such as reasoning, memory and other mental abilities which may be due to trauma or normal ageing. Alzheimer’s disease is one of the most dangerous mental disorders which accounts to 60-80% of mental disorders. Diagnosis of this disease at an early stage will help the patients to lead a quality life for the remaining tenure of their life. The focus of the work is to have a review on different neuro psychological tests, the various algorithms used for the purpose of diagnosis, and the tool that may be used for the analysis.

Alzheimer’s disease, Diagnosis, MCI

[1] Hardy J. “Alzheimer’s disease: the amyloid cascade hypothesis: anupdate and reappraisal”, J Alzheimers Dis;3:151–3, 2006.
[2] Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W,et al. “The Alzheimer’s disease neuroimaging initiative”. Neuroimag-ing Clin N Am;15:869–77. xi–xii, 2005.
[3] Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ,Shaw L, et al. “The Alzheimer’s Disease Neuroimaging Initiative:progress report and future plans”. Alzheimers Dement 2010;6.202.e7–11.e7.
[4] Frisoni GB, Weiner MW. “Alzheimer’s disease neuroimaging initiative special issue”. Neurobiol Aging 2010;31:1259–62.
[5] Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE,Ivnik RJ, et al. “Mild cognitive impairment: ten years later”. Arch Neurol 2009;66:1447–55.
[6] Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S,et al. “Alzheimer’s DiseaseNeuroimaging Initiative biomarkers asquantitative phenotypes: genetics core aims, progress, and plans”. Alzheimers Dement 2010;6(3):265–73.
[7] Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H,et al. “Biological markers of amyloid beta-related mechanisms in Alzheimer’s disease”. Exp Neurol 2010;223:334–46.
[8] Clark CM, Davatzikos C, Borthakur A, Newberg A, Leight S,Lee VM, et al. “Biomarkers for early detection of Alzheimer pathology”. Neurosignals 2008;16:11–8.
[9] Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS. “Applications of neuroimaging to disease modification trials in Alzheimer’sdisease”. Behav Neurol 2009;21:129–36.
[10] Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. “Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics”. Nat Rev Drug Discov 2007;6:295–303.
[11] Petersen RC, Jack CR Jr. “Imaging and biomarkers in early Alzheimer’s disease and mild cognitive impairment”. Clin PharmacolTher 2009;86:438–41.
[12] Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM,Aisen PS, Petersen RC, et al. “Update on the biomarker core of theAlzheimer’s Disease Neuroimaging Initiative subjects”. AlzheimersDement 2010;6:230–8.
[13] Hardy J, Selkoe DJ. “The amyloid hypothesis of Alzheimer’s disease:progress and problems on the road to therapeutics”. Science 2002;297:353–6.
[14] Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS,Weiner MW, et al. “Hypothetical model of dynamic biomarkersof the Alzheimer’s pathological cascade”. Lancet Neurol 2010;9:119–28.
[15] Shaw LM. “PENN biomarker core of the Alzheimer’s disease Neuroimaging Initiative”. Neurosignals 2008;16:19–23
[16] Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML,Knopman DS, et al. “Serial PIB and MRI in normal, mild cognitiveimpairment and Alzheimer’s disease: implications for sequenceof pathological events in Alzheimer’s disease”. Brain 2009;132:1355–65.
[17] Braak H, Del Tredici K. “The pathological process underlying Alzheimer’s disease in individuals under thirty”. Acta Neuropathol, 2011;121:171–81.
[18] Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. “Revising the definition of Alzheimer’s disease:a new lexicon”. Lancet Neurol, 2010;9:1118–27.
[19] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM,et al. “Toward defining the preclinical stages of Alzheimer’s disease:recommendations from the National Institute on Aging-Alzheimer’sAssociation workgroups on diagnostic guidelines for Alzheimer’sdisease”. Alzheimers Dement 2011;7:280–92.
[20] Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS,Boeve BF, et al. “The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics”. Neuroepidemiology, 2008;30:58–69.
[21] Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH,Pankratz VS, et al. “Prevalence of mild cognitive impairment ishigher in men. The Mayo Clinic Study of Aging”. Neurology 2010;75:889–97.
[22] Games D, Adams D, Alessandrini R, Barbour R, Berthelette P,Blackwell C, et al. “Alzheimer-type neuropathology in transgenicmice overexpressing V717F beta-amyloid precursor protein”. Nature, 1995;373:523–7.
[23] Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD,et al. “Biological markers for therapeutic trials in Alzheimer’s disease.Proceedings of the biological markers working group; NIA initiativeon neuroimaging in Alzheimer’s disease”. Neurobiol Aging 2003;24:521–36.
[24] Trojanowski J. “Searching for the biomarkers of Alzheimer’s”. PractNeurol;3:30–4, 2004.
[25] Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. “Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative”. Cogn Dement;5:56–62, 2006.
[26] Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H,Blennow K. “Core candidate neurochemical and imaging biomarkersof Alzheimer’s disease”. Alzheimers Dement;4:38–48, 2008.
[27] Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP,et al. “Imaging brain amyloid in Alzheimer’s disease with PittsburghCompound-B”. Ann Neurol;55:306–19, 2004.
[28] Klunk WE, Mathis CA. “The future of amyloid-beta imaging: a tale ofradionuclides and tracer proliferation”. Curr Opin Neurol;21:683–7, 2008.
[29] Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF. “Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer’s disease”. Brain Res;1025:98–105, 2004.
[30] Schmidt ME, Siemers E, Snyder PJ, Potter WZ, Cole P, Soares H. “The Alzheimer’s Disease Neuroimaging Initiative: perspectives of the Industry Scientific Advisory Board”. Alzheimers Dement;6:286–90, 2010.
[31] Carrillo MC, Sanders CA, Katz RG. “Maximizing the Alzheimer’s Disease Neuroimaging Initiative II”. Alzheimers Dement;5:271–5, 2009.
[32] Toga AW, Crawford KL. “The informatics core of the Alzheimer’s Disease Neuroimaging Initiative”. Alzheimers Dement;6:247–56, 2010.
[33] Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, et al. “Update on the magnetic resonance imagingcore of the Alzheimer’s disease neuroimaging initiative”. AlzheimersDement;6:212–20, 2010.
[34] Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA,et al. “The Alzheimer’s Disease Neuroimaging Initiative positronemission tomography core”. Alzheimers Dement;6:221–9, 2010.
[35] Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R,Thomas RG, et al. “Clinical core of the Alzheimer’s Disease Neuroimaging Initiative: progress and plans”. Alzheimers Dement;6:239–46, 2010.
[36] Cairns NJ, Taylor-Reinwald L, Morris JC. “Autopsy consent, braincollection, and standardized neuropathologic assessment of ADNIparticipants: the essential role of the neuropathology core”. Alzheimers Dement;6:274–9, 2010.
[37] Cummings JL. “Integrating ADNI results into Alzheimer’s diseasedrug development programs”. Neurobiol Aging;31:1481–92, 2010.
[38] Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W,et al. “Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI)”. AlzheimersDement;1:55–66, 2005.
[39] Petersen RC, Trojanowski JQ. “Use of Alzheimer disease biomarkers:potentially yes for clinical trials but not yet for clinical practice”.JAMA;302:436–7, 2009.